Radiolabeled Monoclonal Antibody Imaging of Tumors and Positron Emission Tomogra

肿瘤放射性标记单克隆抗体成像和正电子发射断层扫描

• 批准号: 6431793
• 负责人: JORGE A. CARRASQUILLO
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6431793
• 关键词: antitumor antibody; athymic mouse; clinical research; clinical trial phase I; human subject; immunoglobulin G; monoclonal antibody; neoplasm /cancer immunotherapy; neoplasm /cancer radionuclide diagnosis; neoplasm /cancer radionuclide therapy; neoplasm /cancer transplantation; nuclear medicine; radiation therapy dosage; radionuclide imaging /scanning; radiopharmacology; xenotransplantation; yttrium

These studies are designed to develop improved methods for detecting and treating malignancies. Our group performs preclinical evaluation of antibodies that appear to be promising after initial screening by various laboratories at the National Cancer Institute and develops these antibodies for clinical application. The clinical trials evaluating their pharmacokinetics and dosimetry are performed by our group. A collaborative radioimmunotherapy trial with Dr. Waldmann (PI), in which we used humanized anti-tac monoclonal antibody, is ongoing. Various protocols using [F-18] FDG in PET and [O-15] water for tumor detection, followup, and blood flow measurements are ongoing. We have begun preclinical studies evaluating pretargeting of antibodies for tumor therapy and have demonstrated therapeutic responses with Y-90 and Bi-213.

这些研究旨在开发检测和治疗恶性肿瘤的改进方法。我们小组对经过国家癌症研究所不同实验室初步筛选后似乎有希望的抗体进行临床前评估，并开发这些抗体用于临床应用。评价其药代动力学和剂量学的临床试验由本课题组进行。一项与Waldmann博士(PI)合作的放射免疫治疗试验正在进行中，在试验中我们使用了人源化的抗TAC单抗。在PET中使用[F-18]FDG和[O-15]水进行肿瘤检测、随访和血流测量的各种方案正在进行中。我们已经开始了临床前研究，评估用于肿瘤治疗的抗体的前靶向，并展示了Y-90和Bi-213的治疗效果。